17.80
-1.66%
Close of 9 Nov 2026, in TWD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Twi Biotechnology
Its shares trade on Taipei Exchange under the ticker 6610.TWO. It has been listed since 27 December 2016. In the fiscal year to 31 December 2021, it reported revenue of TWD 66.4m and a net loss of TWD 15.3m. At that date it held total assets of TWD 311.0m and shareholders' equity of TWD 278.8m.
TWi Biotechnology, Inc. engages in the research and development of repositioned drugs for unmet medical needs, especially in rare diseases associated with innate immunity. The company is headquartered in Taipei City, Taipei. The company went IPO on 2016-12-27. The firm is building its product pipeline through in-licensing and internal research. Its product development pipeline includes two drug candidates for treating type II diabetes, arthritis, and immunodermatology diseases and others. It’s still in the research and development stage, its operating income is the contract revenue from the signing of the contract with the Castal Creek Pharmaceuticals (CCP) about its drug AC-203 for the treatment of epidermolysis bullosa (EB). The company mainly aims at America market.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Biotechnology
- Listed since
- 27 Dec 2016
- Website
- twibiotech.com ↗
Leadership
Pay as last reported
- Ms. Yijun WuChairman of the Board, since 2019
- Mr. Cheng-En TsaiGeneral Manager, Chief Medical Officer
- Lijuan HuangHead of Accounting
- Jiaqing ChenDirector
- Peizhi ChenDirector
- Yuru YangDirector
- Yue YueDirector
- Jiazong WangIndependent Director
- Liyan ZhangIndependent Director
- Mr. Senxiong ZhangIndependent Director
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Twilight Biotechnology Inc. focuses on repositioned drugs for rare diseases in innate immunity.
- The company has two drug candidates targeting type II diabetes, arthritis, and immunodermatology.
- Contract revenue from Castal Creek Pharmaceuticals for AC-203 treatment of epidermolysis bullosa provides early income.
Weaknesses
- The company remains in the research and development stage with no commercial products yet.
- Operating income relies solely on a single contract with Castal Creek Pharmaceuticals.
- Limited product pipeline with only two drug candidates in development.
Opportunities
- Expanding the product pipeline through in-licensing and internal research.
- Growing market for rare disease treatments in the United States.
- Increasing demand for immunodermatology and arthritis therapies.
Threats
- Dependence on a single contract with Castal Creek Pharmaceuticals for revenue.
- Competition in the biotechnology sector for rare disease treatments.
- Regulatory challenges in developing new drug candidates.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.